Servier full year 2021/22 results confirm the transformation trajectory of the Group
Discover our news
Servier and Taiho Oncology Present Overall Survival Data for Trifluridine/Tipiracil (LONSURF®) In Combination With Bevacizumab in Patients With Refractory Metastatic Colorectal Cancer at 2023 ASCO Gastrointestinal Cancers Symposium
Real-World Analysis Suggests Pediatric-Inspired Regimens Lead to Higher Overall Survival in Adolescent and Young Adult Patients with Newly-Diagnosed Acute Lymphoblastic Leukemia
Servier Presents Patient Follow Up Data from the Phase 3 AGILE Study at ASH 2022
Servier Wins Reuters’ 2022 Patient Champion Award
New Data at ASH 2022 Bolster Servier’s Leadership in Hematology Research
Servier Affirms Commitment to Cancer by Announcing the Opening of a Global R&D Center and Expanded Offices in Boston’s Seaport
Servier to Showcase Growing Oncology Portfolio at the ASCO and EHA 2022 Annual Meetings
Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Newly Diagnosed IDH1-mutated Acute Myeloid Leukemia